Position in ALMS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$7,625,265
+$7,625,265 QoQ
Shares Held
346,131
Ownership
0.271%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Derivatives in ALMS
reported options exposure · as of Mar 31, 2026CallValue
$1,698,513
CallShares
77,100
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026BOOTHBAY FUND MANAGEMENT, LLC holds $541,743,620 across 143 Biotechnology names. ALMS ranks #17 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
472,961 | $52,664,207 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
438,595 | $42,653,363 | |
| 3 | EXEL |
Exelixis, Inc.
|
803,866 | $34,477,812 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
522,019 | $30,334,524 | |
| 5 | MLYS |
Mineralys Therapeutics, Inc.
|
1,001,728 | $27,136,811 | |
| 6 | TERN |
Terns Pharmaceuticals, Inc.
|
486,170 | $25,630,882 | |
| 7 | CGEM |
Cullinan Therapeutics, Inc.
|
1,112,803 | $15,812,930 | |
| 8 | XENE |
Xenon Pharmaceuticals Inc.
|
270,412 | $15,724,457 |
All Filings in ALMS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7,625,265 | 346,131 | Shares | Other | 2026-05-15 | |
| 2026-03-31 | $1,698,513 | 77,100 | Call | Other | 2026-05-15 | |
| 2025-12-31 | $566,080 | 58,000 | Put | Other | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||